In Refractory GIST, Regorafenib Delays Disease Progression Across All Subgroups

The multi-tyrosine kinase inhibitor regorafenib significantly delays disease progression in virtually all subgroups of patients with gastrointestinal stromal tumor (GIST) in the second-line setting, and may even confer benefits when continued after progression, according to subgroup and post-progression analyses of the phase III GRID trial presented at the ESMO 2012 Congress. The current exploratory analyses were presented at ESMO 2012 by Peter Reichardt, MD, PhD, of HELIOS Klinikum in Bad Saarow, Germany. Read more at OncLive. At OncLive there are also related articles and videos on different aspects of GIST treatment available.

Member LogIn